Search by Abstract Number Results

Abstract Number: 0866 • ACR Convergence 2024
Cross-sectional Analysis of Erosive Hand Osteoarthritis and Fracture Risk
Avanika Mahajan¹, carolyn mead harvey², Chris Grilli³ and Megan Sullivan³, ¹Mayo Clinic - - Scottsdale, AZ, Phoenix, AZ, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is a subtype of hand OA that primarily impacts the interphalangeal joints resulting in subchondral bone erosion and cortical destruction.…
Abstract Number: 0866 • ACR Convergence 2023
A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies
André Tiaden¹, Simone Häner Massimi¹, Ulrich Walker², Diego Kyburz³ and Stavros Giaglis¹, ¹Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, ²Basel University Hospital, Basel, Switzerland, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Autoimmunity, trauma, or infection lead to devastating arthropathies, within enormous socioeconomic impact due to its high frequency and chronicity. The development of novel treatments…
Abstract Number: 0866 • ACR Convergence 2022
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
Sheila Angeles-Han¹, Grant Schulert¹, Megan Quinlan-Waters¹, Alexandra Duell¹, Jennifer Huggins¹, Tiffany Nguyen², Cameron Sapp², Sumit Sharma³, Sunil Srivastava⁴ and Arjun Sood², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cole Eye Institute, Cleveland Clinic, Cleveland, OH, ⁴Cole Eye Institute, Cleveland Clinic, Cincinnati, OH
Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
Abstract Number: 0866 • ACR Convergence 2021
Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Cristina Reategui-Sokolova⁵, Ann Clarke⁶, Leanna Wise⁷, Guillermo Pons-Estel⁸, Maria José Santos⁹, Sasha Bernatsky¹⁰, Sandra Lúcia Ribeiro¹¹, Samar Al Emadi¹², Jeffrey Sparks¹³, Tiffany Hsu¹⁴, Kristin D'Silva¹⁵, Naomi Patel¹⁵, Emily Gilbert¹⁶, Maria Valenzuela-Almada¹⁷, Andreas Jnsen¹⁸, Gianpiero Landolfi¹⁹, Micaela Fredi²⁰, Tiphaine Goulenok²¹, Mathilde Devaux²², Xavier Mariette²³, Viviane Queyrel²⁴, Vasco C Romão²⁵, Graça Sequeira²⁶, Rebecca Hasseli²⁷, Bimba Franziska Hoyer²⁸, Reinhard Voll²⁹, Christof Specker³⁰, Roberto Baez³¹, Vanessa Castro Coello³², Edgard Neto³³, Gilda Ferreira³⁴, Odirlei Andre Monticielo³⁵, Emily Sirotich³⁶, Jean Liew³⁷, Jonathan Hausmann³⁸, Paul Sufka³⁹, Rebecca Grainger⁴⁰, Suleman Bhana⁴¹, Wendy Costello⁴², Zachary Wallace⁴³, Lindsay Jacobsohn⁴⁴, Anja Strangfeld⁴⁵, Elsa Frazão Mateus⁴⁶, Kimme Hyrich⁴⁷, Laure Gossec⁴⁸, Loreto Carmona¹, Saskia Lawson-Tovey⁴⁷, Lianne Kearsley-Fleet⁴⁹, Martin Schaefer⁵⁰, Pedro Machado⁵¹, Philip Robinson⁵², Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶University of Calgary, Calgary, AB, Canada, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR), Rosario, Argentina, ⁹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰McGill University, Montréal, QC, Canada, ¹¹Universidade Federal do Amazonas, Amazonas, Brazil, ¹²Hamad medical corporation, Doha, Qatar, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁵Massachusetts General Hospital, Boston, MA, ¹⁶Mayo Clinic, Jacksonville, FL, ¹⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Lund University, Lund, Sweden, ¹⁹Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Internal Medicine Department, Bichat Claude Bernard Hospital, Paris, France, ²²Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France, ²³Université Paris- Saclay, Rheumatology, Paris, France, ²⁴University Hospital of Nice, Nice, France, ²⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²⁶Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, ²⁷Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁸Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ³⁰Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ³¹Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina, ³²Sanatorio Güemes, Buenos Aires, Argentina, ³³UNIFESP, São Paulo, Brazil, ³⁴Federal University of Minas Gerais, Belo Horizonte, Brazil, ³⁵Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³⁶McMaster University, Hamilton, ON, Canada, ³⁷Boston University, Boston, MA, ³⁸Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ³⁹HealthPartners, Eagan, MN, ⁴⁰University of Otago, Wellington, New Zealand, ⁴¹Crystal Run Health, Montvale, NJ, ⁴²Irish Children's Arthritis Network, Bansha, Ireland, ⁴³Massachusetts General Hospital, Newton, MA, ⁴⁴University of California San Francisco, Antioch, CA, ⁴⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁶Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁴⁷University of Manchester, Manchester, United Kingdom, ⁴⁸Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁴⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁰German Rheumatism Research Center, Berlin, Germany, ⁵¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵²Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Preliminary data in people with SLE suggested that disease activity as well as SLE treatment at time of COVID-19 acquisition impact COVID-19 outcomes over…
Abstract Number: 0866 • ACR Convergence 2020
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies
Joan Merrill¹, Matthew Studham², Eric Morand³, Aida Aydemir², Cristina Vazquez Mateo², Alex Rolfe², Amy Kao² and Robert Townsend², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].